TG003

• Description:

  TG003 is a potent inhibitor of Clk1/Sty; inhibits Clk1 and Clk4 with IC50 values of 20 and 15 nM, respectively[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319

• Target:

  CDK

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/TG003.html

• Purity:

  99.57

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  CC(/C=C1SC2=CC=C(C=C2N\1CC)OC)=O

• Molecular Formula:

  C13H15NO2S

• Molecular Weight:

  249.33

• Precautions:

  H302, H315, H319

• References & Citations:

  [1]Muraki M, et al. Manipulation of alternative splicing by a newly developed inhibitor of Clks. J Biol Chem. 2004 Jun 4;279 (23) :24246-54.|[2]Marcel V, et al. Modulation of p53β and p53γ expression by regulating the alternative splicing of TP53 gene modifies cellular response. Cell Death Differ. 2014 Sep;21 (9) :1377-87.|[3]Kurihara T, et al. Alleviation of behavioral hypersensitivity in mouse models of inflammatory pain with two structurally different casein kinase 1 (CK1) inhibitors. Mol Pain. 2014 Mar 10;10:17.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  CLK

• CAS Number:

  719277-26-6